RESUMEN
This guideline updates and widens the scope of the previ-ous British Society for Haematology (BSH) Clinical guide-lines for Diagnosis and Management of Heparin-Induced Thrombocytopenia: Second Edition1 to include functional assays in the diagnosis of heparin-induced thrombocytope-nia (HIT), when to use direct-acting oral anti-coagulants, and the role of intravenous (IV) immunoglobulins and plasma exchange in the management of HIT and spontane-ous HIT.HIT is an immune-mediated, highly pro-thrombotic dis-order of platelet activation caused by pathogenic antibodies against a platelet factor 4 (PF4)heparin complex. It is the most frequent drug-induced immune thrombocytopenia and may lead to life-threatening thrombosis. There are two distinct forms of HIT: type I, also known as heparin-asso-ciated thrombocytopenia, which is a non-immunological response to heparin treatment, mediated by a direct interac-tion between heparin and circulating platelets causing plate-let clumping or sequestration, and type II, which is immune mediated.
Asunto(s)
Humanos , Trombocitopenia/tratamiento farmacológico , Plaquetas/efectos de los fármacos , Trombocitopenia/diagnóstico , Inmunoglobulinas/análisis , Factor Plaquetario 4/análisis , Heparina/uso terapéuticoRESUMEN
Heparin-induced thrombocytopenia (HIT) is a relatively common prothrombotic adverse drug reaction of unusual pathogenesis that features platelet-activating immunoglobulin G antibodies. The HIT immune response is remarkably transient, with heparin-dependent antibodies no longer detectable 40 to 100 days (median) after an episode of HIT, depending on the assay performed. Moreover, the minimum interval from an immunizing heparin exposure to the development of HIT is 5 days irrespective of the patient's previous heparin exposure status or history of HIT. This means that short-term heparin reexposure can be safely performed if platelet-activating antibodies are no longer detectable at reexposure baseline and is recommended when heparin is the clear anticoagulant of choice, such as for cardiac or vascular surgery. The risk of recurrent HIT 1 to 2 weeks after heparin reexposure is â¼2% to 5% and is attributable to formation of delayed-onset (or autoimmune-like) HIT antibodies that activate platelets even in the absence of pharmacologic heparin. Some studies suggest that longer-term heparin reexposure (eg, for chronic hemodialysis) may also be reasonable. However, for other antithrombotic indications that involve patients with a history of HIT (eg, treatment of venous thromboembolism or acute coronary syndrome), preference should be given to non-heparin agents such as fondaparinux, danaparoid, argatroban, bivalirudin, or one of the new direct-acting oral anticoagulants as appropriate.
Asunto(s)
Anticoagulantes/uso terapéutico , Plaquetas , Heparina/efectos adversos , Inmunoglobulina G , Activación Plaquetaria , Trombocitopenia , Administración Oral , Plaquetas/inmunología , Plaquetas/metabolismo , Heparina/uso terapéutico , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Activación Plaquetaria/efectos de los fármacos , Activación Plaquetaria/inmunología , Trombocitopenia/sangre , Trombocitopenia/inducido químicamente , Trombocitopenia/tratamiento farmacológico , Trombocitopenia/inmunología , Factores de TiempoRESUMEN
Hypercoagulable states can be inherited or acquired. Inherited hypercoagulable states can be caused by a loss of function of natural anticoagulant pathways or a gain of function in procoagulant pathways. Acquired hypercoagulable risk factors include a prior history of thrombosis, obesity, pregnancy, cancer and its treatment, antiphospholipid antibody syndrome, heparin-induced thrombocytopenia, and myeloproliferative disorders. Inherited hypercoagulable states combine with acquired risk factors to establish the intrinsic risk of venous thromboembolism for each individual. Venous thromboembolism occurs when the risk exceeds a critical threshold. Often a triggering factor, such as surgery, pregnancy, or estrogen therapy, is required to increase the risk above this critical threshold.
Asunto(s)
Complicaciones Hematológicas del Embarazo/terapia , Trombofilia/etiología , Trombofilia/terapia , Trombosis/prevención & control , Síndrome Antifosfolípido/complicaciones , Antitrombinas/sangre , Factor V/genética , Femenino , Heparina/efectos adversos , Humanos , Neoplasias/complicaciones , Embarazo , Deficiencia de Proteína C/genética , Deficiencia de Proteína S/genética , Protrombina/genética , Trombocitopenia/inducido químicamente , Trombocitopenia/complicaciones , Trombofilia/genética , Trombofilia/inmunologíaRESUMEN
Microparticles (MPs) are considered to be important biological effectors of several different physiological and pathological processes. There is increasing evidence of their role in haemostasis and thrombosis, and also of their importance in cancer cell survival, invasiveness and metastasis. The level of circulating MPs has been assessed in many different disease states, and there are reports that patients with malignancy and patients with thrombosis have increased levels of circulating MPs and MP-dependent thrombogenic potential. Research into the function and effect of MPs is currently hampered by a lack of standardization in the methods used to identify and quantify them. As these methods improve it is likely that MP assays will be of use both diagnostically and therapeutically in the future.
Asunto(s)
Micropartículas Derivadas de Células/fisiología , Neoplasias/fisiopatología , Trombosis/fisiopatología , Micropartículas Derivadas de Células/inmunología , Femenino , Humanos , Inmunofenotipificación , Masculino , Neoplasias/complicaciones , Trombosis/etiología , Trombosis/inmunologíaRESUMEN
Hypercoagulable states can be inherited or acquired. Inherited hypercoagulable states can be caused by a loss of function of natural anticoagulant pathways or a gain of function in procoagulant pathways. Acquired hypercoagulable risk factors include a prior history of thrombosis, obesity, pregnancy, cancer and its treatment, antiphospholipid antibody syndrome, heparin-induced thrombocytopenia, and myeloproliferative disorders. Inherited hypercoagulable states combine with acquired risk factors to establish the intrinsic risk of venous thromboembolism for each individual. Venous thromboembolism occurs when the risk exceeds a critical threshold. Often a triggering factor, such as surgery, pregnancy, or estrogen therapy, is required to increase the risk above this critical threshold.
Asunto(s)
Trastornos de la Coagulación Sanguínea Heredados/complicaciones , Trombofilia/complicaciones , Trombosis de la Vena/etiología , Síndrome Antifosfolípido/etiología , Trastornos de la Coagulación Sanguínea Heredados/fisiopatología , Anticonceptivos Femeninos/efectos adversos , Terapia de Reemplazo de Estrógeno/efectos adversos , Femenino , Humanos , Tamizaje Masivo , Neoplasias/fisiopatología , Embarazo , Complicaciones Hematológicas del Embarazo/fisiopatología , Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos , Trombocitopenia/inducido químicamente , Trombofilia/diagnóstico , Trombofilia/tratamiento farmacológico , Trombofilia/genéticaRESUMEN
A 57-year-old man developed transient global amnesia within an hour of bolus unfractionated heparin administration on day 4 post-mitral valve replacement. Both immunoglobulin G-specific enzyme-linked immunosorbent assay and serotonin release assay were strongly positive for the antibodies that cause heparin-induced thrombocytopenia. The patient's cognitive functions returned to normal following discontinuation of unfractionated heparin and warfarin and commencement of lepirudin infusion.
Asunto(s)
Amnesia Global Transitoria/diagnóstico , Anticoagulantes/efectos adversos , Heparina/efectos adversos , Trombocitopenia/complicaciones , Warfarina/efectos adversos , Amnesia Global Transitoria/inducido químicamente , Anticoagulantes/uso terapéutico , Implantación de Prótesis de Válvulas Cardíacas , Hirudinas , Humanos , Masculino , Persona de Mediana Edad , Válvula Mitral/patología , Proteínas Recombinantes/uso terapéutico , Trombocitopenia/inducido químicamente , Factores de TiempoRESUMEN
Low-molecular-weight heparin (LMWH) inhibits the activity of the intrinsic factor X activation complex, a property that persists when LMWH is rendered low affinity (LA) for antithrombin, but is reduced when it is N-desulfated. When LA-LMWH is hypersulfated (sLA-LMWH), its potency against intrinsic tenase is increased and it acquires inhibitory activity against prothrombinase. sLA-LMWH functions by interfering with the association of enzyme and cofactor in both activation complexes. In a rabbit carotid artery thrombosis prevention model, sLA-LMWH is superior to LMWH. Because of its low affinity for antithrombin and multiple sites of action, sLA-LMWH may prove to be safer and more effective than other anticoagulants.
Asunto(s)
Anticoagulantes/farmacología , Antitrombinas/efectos de los fármacos , Antitrombinas/farmacología , Coagulación Sanguínea/efectos de los fármacos , Heparina de Bajo-Peso-Molecular/farmacología , Animales , Anticoagulantes/uso terapéutico , Antitrombinas/uso terapéutico , Factores de Coagulación Sanguínea/efectos de los fármacos , Trombosis de las Arterias Carótidas/tratamiento farmacológico , Cisteína Endopeptidasas/efectos de los fármacos , Heparina de Bajo-Peso-Molecular/uso terapéutico , Humanos , Proteínas de Neoplasias/efectos de los fármacosRESUMEN
Deficiency in a coagulation factor VIII (FVIII) causes a genetic disorder hemophilia A, which is treated by repeated infusions of expensive FVIII products. Recombinant FVIII (rFVIII), the culmination of years of extensive international research, is an important alternative to plasma-derived FVIII (pdFVIII) and is considered to have a higher margin of safety. Advances in biotechnology allowed production of rFVIII at industrial scale, which significantly improved treatment of hemophilia A patients. We review the contemporary methods used for FVIII expression in mammalian cell culture systems and discuss the factors responsible for insufficient recoveries of rFVIII, such as inefficient accumulation of FVIII mRNA in the cell, complexity of the mechanisms of FVIII secretion, and instability of secreted FVIII. The approaches to improve the yield of rFVIII in cell culture systems include genetic engineering of B-domain-deleted FVIII, introduction of introns into FVIII cDNA constructs for more efficient processing and accumulation of FVIII mRNA, and introduction of mutations into chaperone-binding sites of FVIII to improve its secretion. Design of FVIII with prolonged half-life in vivo is considered as another promising direction in improving rFVIII protein and efficiency of hemophilia A therapy. As an alternative to expression of rFVIII in cell culture systems, we discuss production of rFVIII in transgenic animals, where high levels of rFVIII have been successfully secreted into milk. We also pay attention to the major limitations of this approach, such as safety issues associated with potential transmission of animal pathogens. Finally, we present a brief characterization of commercial recombinant FVIII products currently available on the market for hemophilia A treatment.